AZD1390

Research use only, not for human use.

AZD1390 (AZD-1390) is a novel potent, selective, orally available and CNS penetrant ATM inhibitor with IC50 of 0.78 nM.Brain Cancer,Phase 1 Clinical

AZD1390 (AZD-1390) is a novel potent, selective, orally available and CNS penetrant ATM inhibitor with IC50 of 0.78 nM, displays >1,000-fold selectivity over closely related (PIKKs) and distant kinases; radiosensitises a panel of glioblastoma multiforme (GBM) cell lines and NCI-H2228 lung cells (IC50=3 nM); demonstrates potential in combination with radiation therapy for the treatment of brain tumors.Brain Cancer,Phase 1 Clinical(In Vivo):Median survival of mice treated with AZD1390 and radiation are significantly longer than untreated control mice (p=0.001). No overt signs of treatment toxicity are observed with small animal radiation research platform (SARRP) contrary to wholehead irradiated mice that seem to develop mucositis and difficulties drinking and eating at doses >10 Gy in combination with AZD1390.

——

Median survival of mice treated with AZD1390 and radiation are significantly longer than untreated control mice (p=0.001). No overt signs of treatment toxicity are observed with small animal radiation research platform (SARRP) contrary to wholehead irradiated mice that seem to develop mucositis and difficulties drinking and eating at doses >10 Gy in combination with AZD1390.

AZD 1390 | AZD-1390

Cell Cycle/DNA Damage

ATM/ATR

ATM

Cancer

Brain Cancer

2089288-03-7

477.584

C27H32FN5O2

>98% (HPLC)

DMSO: 20 mg/mL, Need ultrasonic and warming （ < 1 mg/ml refers to the product slightly soluble or insoluble )

O=C(N1C(C)C)N(C)C2=C1C3=CC(C4=CC=C(OCCCN5CCCCC5)N=C4)=C(F)C=C3N=C2

2H-Imidazo[4,5-c]quinolin-2-one,7-fluoro-1,3-dihydro-3-methyl-1-(1-methylethyl)-8-[6-[3-(1-piperidinyl)propoxy]-3-pyridinyl]-

(-20℃)

With Ice Pack

≥ 2 years